Drug intelligence / Profile preview

Stulln

Development stage: Phase 2
Modality: Small Molecules
Administration: Ophthalmic

Overview

Stulln is an ophthalmic combination drug, available as eyedrops or an eye tonic, that has been approved in Europe and China for the treatment of visual discomfort and retinal macular diseases. Its active ingredients are Digitalisglycosides (DGS) and Esculin. Digitalisglycosides are known to enhance muscular contraction, while Esculin improves microvascular circulation. These combined actions are believed to improve ciliary functions, leading to enhanced accommodative amplitude, facility, and endurance in the eye.

Brand names: Stulln
Other names: Stulln eyedropsStulln eye tonic

Beyond the preview

Go deeper on Stulln.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stulln.

Explore the full profile